OBJECTIVE: Several studies have assessed the effect of angiotensin converting enzyme inhibitors (ACEIs) on @entity409 as measured by brachial @entity450 ( @entity450 ). We conducted a meta-analysis to investigate this effect in comparison to placebo or no treatment and to other antihypertensive agents. METHODS: MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from 1996 to October 2010 on randomised controlled trials (RCTs) that assessed the effect of ACEIs on @entity450 versus placebo or no treatment and ACEIs versus angiotensin receptor blockers (ARBs), @entity460 channel blockers (CCBs) and b-blockers. Data from included studies were pooled with use of random effects meta-analysis of the weighted mean change differences between the comparator groups. Heterogeneity across studies was assessed with the I(2) statistic. RESULTS: In 10 trials including 1129 @entity1 , treatment with ACEIs (n = 498) versus placebo or no treatment (n = 503) significantly improved @entity450 (pooled mean change difference 1.26%, 95% C.I. 0.46-2.07, p = 0.002 with significant heterogeneity). In 11 trials which included 805 @entity1 , treatment with ACEIs (n = 264) had a significant effect on @entity450 when compared with other antihypertensives (ARBs, CCBs and b-blockers) (n = 420) (pooled mean change difference 0.89%, 95% C.I. 0.22-1.56, p = 0.009, I(2) = 83%, p for heterogeneity < 0.00001). In 7 trials, treatment with ACEIs had no significant effect on @entity450 when compared with ARBs (pooled mean change difference = 0.21%, 95% C.I. -0.24 to 0.66, p = 0.36, I(2) = 0%). However, in 4 trials ACEIs significantly improved @entity450 when compared with CCBs (pooled mean change difference 2.15%, 95% C.I. 0.55-3.75, p = 0.009, I(2) = 90%, p for heterogeneity < 0.00001). When compared with b-blockers in 4 trials, ACEIs also had a significant effect on @entity450 (pooled mean change difference = 0.59%, 95% C.I. 0.05-1.13, p = 0.03, I(2) = 34%, p for heterogeneity = 0.21). CONCLUSIONS: This study shows that ACEIs improve @entity450 which is a marker of endothelial function in @entity1 with @entity409 caused by various conditions and are superior to CCBs and b-blockers. There was no significant difference between ACEIs and ARBs effect on @entity450 .

Angiotensin converting enzyme inhibitors effect on XXXX : a meta-analysis of randomised controlled trials.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium'] @entity409 :: ('MESH:D008107', 'Disease') :: ['endothelial dysfunction'] @entity450 :: ('MESH:D006940', 'Disease') :: ['brachial FMD', 'flow-mediated vasodilatation', 'FMD']
@entity409 :: (MESH:D008107,Disease) :: ['endothelial dysfunction']
